Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Edema 1Brain Neoplasms 1Brain Edema 1

Interventions

pembrolizumab 185Carboplatin 131Paclitaxel 123Gemcitabine 122Docetaxel 97Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 65Bevacizumab 65Capecitabine 60atezolizumab 55fludarabine 49Fluorouracil 49Azacitidine 49130-nm albumin-bound paclitaxel 43Irinotecan 42venetoclax 41Trastuzumab 41Cetuximab 40Leucovorin 37Ipilimumab 36Erlotinib Hydrochloride 35Oxaliplatin 32Fulvestrant 32Cytarabine 32avelumab 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Corticotropin-Releasing Hormone × Clear all
NCT01369121 2013-07-30

Tolerability Study of Xerecept® in Pediatric Patients

Celtic Pharma Development Services

Phase 1/2 Terminated
15 enrolled
CNS

Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡